Gagan Joshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gagan Joshi has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Joseph Biederman
Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, MA, USA
15 shared publicationsJanet Wozniak
Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, Boston, MA, USA
12 shared publicationsCarter Petty
Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA
6 shared publicationsMaribel Galdo
Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, Boston, MA, USA
6 shared publicationsRonna Fried
Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, Boston, MA, USA
6 shared publicationsStephannie L. Furtak
Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, 55 Fruit Street, WRN 626, Boston, MA, 02114, USA
5 shared publications
Latest Publications
- Open Access
Caregiver-Rated Inappropriate Speech and Post-cTBS Motor Cortical Facilitation in Autism: A Pilot Biomarker Study
Transcranial magnetic stimulation can provide noninvasive measures of cortical excitability and plasticity, but relationships between these measures and clinically observable features of autism are not fully characterized. Nineteen autistic participants aged 15 to 40 years were included in the analysis of a left primary motor cortex continuous theta-burst stimulation (cTBS) biomarker protocol. Motor evoked potentials were measured at baseline and at seven assessments from 5 to 60 min after stimulation. Linear mixed-effects models evaluated whether clinical measures moderated the post-stimulation motor evoked potential log-response ratio over time. Aberrant Behavior Checklist (ABC) and Attenuated Behavior Questionnaire (ABQ) analyses were restricted to the same 15 participants with caregiver-informant assessments. Catatonia severity, social impairment, ABQ Motor Total, ABQ Total, and cognitive ability did not significantly moderate the post-stimulation response. ABC Inappropriate Speech was associated with progressively greater post-stimulation facilitation (standardized Time-by-Inappropriate Speech interaction: beta = +0.688, SE = 0.210, 95% CI +0.276 to +1.099; Holm-adjusted P = .008 across eight informant-rated models). Two individual speech-related items ("Talks excessively" and "Talks to self loudly") survived false-discovery-rate correction. An exploratory eight-item ABC phenotype showed a large descriptive in-sample association (beta = +0.904, SE = 0.200, P less than .001) and directionally positive held-out performance. However, full-pipeline permutation tests were nonsignificant for both Pearson (r = .357, two-sided empirical P = .360) and Spearman correlations (rho = .446, two-sided empirical P = .261). Caregiver-rated inappropriate speech may be associated with altered post-cTBS motor cortical facilitation in autism. The candidate phenotype remains hypothesis-generating and requires independent validation.
Open AccessCaregiver-Rated Inappropriate Speech and Post-cTBS Motor Cortical Facilitation in Autism: A Pilot Biomarker Study
Transcranial magnetic stimulation can provide noninvasive measures of cortical excitability and plasticity, but relationships between these measures and clinically observable features of autism are not fully characterized. Nineteen autistic participants aged 15 to 40 years were included in the analysis of a left primary motor cortex continuous theta-burst stimulation (cTBS) biomarker protocol. Motor evoked potentials were measured at baseline and at seven assessments from 5 to 60 min after stimulation. Linear mixed-effects models evaluated whether clinical measures moderated the post-stimulation motor evoked potential log-response ratio over time. Aberrant Behavior Checklist (ABC) and Attenuated Behavior Questionnaire (ABQ) analyses were restricted to the same 15 participants with caregiver-informant assessments. Catatonia severity, social impairment, ABQ Motor Total, ABQ Total, and cognitive ability did not significantly moderate the post-stimulation response. ABC Inappropriate Speech was associated with progressively greater post-stimulation facilitation (standardized Time-by-Inappropriate Speech interaction: beta = +0.688, SE = 0.210, 95% CI +0.276 to +1.099; Holm-adjusted P = .008 across eight informant-rated models). Two individual speech-related items ("Talks excessively" and "Talks to self loudly") survived false-discovery-rate correction. An exploratory eight-item ABC phenotype showed a large descriptive in-sample association (beta = +0.904, SE = 0.200, P less than .001) and directionally positive held-out performance. However, full-pipeline permutation tests were nonsignificant for both Pearson (r = .357, two-sided empirical P = .360) and Spearman correlations (rho = .446, two-sided empirical P = .261). Caregiver-rated inappropriate speech may be associated with altered post-cTBS motor cortical facilitation in autism. The candidate phenotype remains hypothesis-generating and requires independent validation.
- Open Access
Cortical Excitation-Inhibition Balance in Autism Varies by Brain Region and Age
Autism spectrum disorder (ASD) is characterized by differences in social communication and interaction, alongside restricted and repetitive behaviors. The hypothesis that ASD is associated with an altered cortical excitation-inhibition (EI) balance has been the subject of extensive investigations, yet the evidence supporting it remains mixed. A key challenge in testing this hypothesis is that the EI balance also changes substantially during typical maturation, from childhood through adolescence and into early adulthood. We used resting-state magnetoencephalography (MEG) recordings to examine the developmental trajectory of cortical EI alterations, with regional specificity, in a large cross-sectional cohort (N = 172), comprised of 92 typically developing (TD) individuals and 80 individuals diagnosed with ASD, spanning ages 6-32. To that end, functional EI (fEI), derived from critical brain dynamics, was estimated across 500 cortical parcellations in cortical space. Group-averaged fEI maps revealed broadly similar large-scale topographic patterns in the TD and ASD groups when averaged across all ages. When divided by age into childhood (6-12 years, N ASD = 18, N TD = 16), adolescence (13-18 years, N ASD = 27, N TD = 41) and adulthood (19-32 years, N ASD = 28, N TD = 26), we found an overall pattern of increased global fEI in childhood and decreased fEI in adolescence in the ASD group, with no evidence of a difference between groups in fEI in adulthood. Additional parcel-wise regression analyses identified a significant main effect of diagnostic group, independent of age, in the right dorsolateral prefrontal cortex, where TD individuals showed higher fEI than those with ASD across all ages. Furthermore, a significant group-by-age interaction was observed in the left inferior parietal cortex, where we found evidence that fEI increased with age in TD individuals (beta = 0.012, p = 0.006) but no evidence of a similar age-dependent increase in those with ASD (beta = 0.001, p = 0.84), indicating diverging developmental trajectories. Finally, fEI in paracentral and precuneus cortical regions was associated with ASD symptom severity. Together, these findings support a scenario in which EI imbalance, as assessed with fEI, is not globally distributed in ASD, and is not static through development, but is instead expressed through regionally and developmentally specific differences, with implications for understanding the neural substrates of ASD phenotypic heterogeneity.
Open AccessCortical Excitation-Inhibition Balance in Autism Varies by Brain Region and Age
Autism spectrum disorder (ASD) is characterized by differences in social communication and interaction, alongside restricted and repetitive behaviors. The hypothesis that ASD is associated with an altered cortical excitation-inhibition (EI) balance has been the subject of extensive investigations, yet the evidence supporting it remains mixed. A key challenge in testing this hypothesis is that the EI balance also changes substantially during typical maturation, from childhood through adolescence and into early adulthood. We used resting-state magnetoencephalography (MEG) recordings to examine the developmental trajectory of cortical EI alterations, with regional specificity, in a large cross-sectional cohort (N = 172), comprised of 92 typically developing (TD) individuals and 80 individuals diagnosed with ASD, spanning ages 6-32. To that end, functional EI (fEI), derived from critical brain dynamics, was estimated across 500 cortical parcellations in cortical space. Group-averaged fEI maps revealed broadly similar large-scale topographic patterns in the TD and ASD groups when averaged across all ages. When divided by age into childhood (6-12 years, N ASD = 18, N TD = 16), adolescence (13-18 years, N ASD = 27, N TD = 41) and adulthood (19-32 years, N ASD = 28, N TD = 26), we found an overall pattern of increased global fEI in childhood and decreased fEI in adolescence in the ASD group, with no evidence of a difference between groups in fEI in adulthood. Additional parcel-wise regression analyses identified a significant main effect of diagnostic group, independent of age, in the right dorsolateral prefrontal cortex, where TD individuals showed higher fEI than those with ASD across all ages. Furthermore, a significant group-by-age interaction was observed in the left inferior parietal cortex, where we found evidence that fEI increased with age in TD individuals (beta = 0.012, p = 0.006) but no evidence of a similar age-dependent increase in those with ASD (beta = 0.001, p = 0.84), indicating diverging developmental trajectories. Finally, fEI in paracentral and precuneus cortical regions was associated with ASD symptom severity. Together, these findings support a scenario in which EI imbalance, as assessed with fEI, is not globally distributed in ASD, and is not static through development, but is instead expressed through regionally and developmentally specific differences, with implications for understanding the neural substrates of ASD phenotypic heterogeneity.
- Open Access
- 10 February 2026
- Published by Elsevier in Journal of Affective Disorders Reports
- Vol. 24
Understanding the natural landscape of the chronology of major depressive disorder and mania in youth
- 10 February 2026
- Published by Elsevier in Journal of Affective Disorders Reports
- Vol. 24
Open AccessUnderstanding the natural landscape of the chronology of major depressive disorder and mania in youth
- 12 October 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 61 (10) , S139
8.1 ASD and ADHD: Diagnosis and Treatment
- 12 October 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 61 (10) , S139
8.1 ASD and ADHD: Diagnosis and Treatment
- 26 September 2022
- Published by Springer Nature in Neuropsychology Review
- Vol. 33 (4) , 834-855
Treatment Response of Transcranial Magnetic Stimulation in Intellectually Capable Youth and Young Adults with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
To examine current clinical research on the use of transcranial magnetic stimulation (TMS) in the treatment of pediatric and young adult autism spectrum disorder in intellectually capable persons (IC-ASD). We searched peer-reviewed international literature to identify clinical trials investigating TMS as a treatment for behavioral and cognitive symptoms of IC-ASD. We identified sixteen studies and were able to conduct a meta-analysis on twelve of these studies. Seven were open-label or used neurotypical controls for baseline cognitive data, and nine were controlled trials. In the latter, waitlist control groups were often used over sham TMS. Only one study conducted a randomized, parallel, double-blind, and sham controlled trial. Favorable safety data was reported in low frequency repetitive TMS, high frequency repetitive TMS, and intermittent theta burst studies. Compared to TMS research of other neuropsychiatric conditions, significantly lower total TMS pulses were delivered in treatment and neuronavigation was not regularly utilized. Quantitatively, our multivariate meta-analysis results report improvement in cognitive outcomes (pooled Hedges’ g = 0.735, 95% CI = 0.242, 1.228; p = 0.009) and primarily Criterion B symptomology of IC-ASD (pooled Hedges’ g = 0.435, 95% CI = 0.359, 0.511; p < 0.001) with low frequency repetitive TMS to the dorsolateral prefrontal cortex. The results of our systematic review and meta-analysis data indicate that TMS may offer a promising and safe treatment option for pediatric and young adult patients with IC-ASD. However, future work should include use of neuronavigation software, theta burst protocols, targeting of various brain regions, and robust study design before clinical recommendations can be made.
- 26 September 2022
- Published by Springer Nature in Neuropsychology Review
- Vol. 33 (4) , 834-855
Treatment Response of Transcranial Magnetic Stimulation in Intellectually Capable Youth and Young Adults with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
To examine current clinical research on the use of transcranial magnetic stimulation (TMS) in the treatment of pediatric and young adult autism spectrum disorder in intellectually capable persons (IC-ASD). We searched peer-reviewed international literature to identify clinical trials investigating TMS as a treatment for behavioral and cognitive symptoms of IC-ASD. We identified sixteen studies and were able to conduct a meta-analysis on twelve of these studies. Seven were open-label or used neurotypical controls for baseline cognitive data, and nine were controlled trials. In the latter, waitlist control groups were often used over sham TMS. Only one study conducted a randomized, parallel, double-blind, and sham controlled trial. Favorable safety data was reported in low frequency repetitive TMS, high frequency repetitive TMS, and intermittent theta burst studies. Compared to TMS research of other neuropsychiatric conditions, significantly lower total TMS pulses were delivered in treatment and neuronavigation was not regularly utilized. Quantitatively, our multivariate meta-analysis results report improvement in cognitive outcomes (pooled Hedges’ g = 0.735, 95% CI = 0.242, 1.228; p = 0.009) and primarily Criterion B symptomology of IC-ASD (pooled Hedges’ g = 0.435, 95% CI = 0.359, 0.511; p < 0.001) with low frequency repetitive TMS to the dorsolateral prefrontal cortex. The results of our systematic review and meta-analysis data indicate that TMS may offer a promising and safe treatment option for pediatric and young adult patients with IC-ASD. However, future work should include use of neuronavigation software, theta burst protocols, targeting of various brain regions, and robust study design before clinical recommendations can be made.
- 11 May 2022
- Published by Elsevier in Child and Adolescent Psychiatric Clinics of North America
- Vol. 31 (3) , 449-468
Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder
- 11 May 2022
- Published by Elsevier in Child and Adolescent Psychiatric Clinics of North America
- Vol. 31 (3) , 449-468
Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder
- 5 May 2022
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 36 (5) , 637-644
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole
Background: Pediatric bipolar disorder (BP) is frequently comorbid with conduct disorder (CD) and its presence adds to the morbidity of BP. While there are no known pharmacological treatments for CD, pediatric BP is responsive to treatment with medications initially indicated for the treatment of psychosis, several of which have Food and Drug Administration (FDA) approval for the treatment of pediatric mania. Aims: The main aim of this secondary analysis was to examine whether pediatric BP comorbid with CD responds similarly to treatment with such selected medications. Considering the well-documented morbidity of CD, this finding could have important clinical and public health significance. Methods: We conducted a secondary analysis of six prospective 8-week open-label trials of selected medications (risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) using identical methodology in youth with BP with and without comorbid CD. Results: Of 165 youths with BP, 54% ( N = 89) met criteria for comorbid CD. The antimanic effects observed did not significantly differ between BP youths with and without comorbid CD, as measured either by a reduction in Young Mania Rating Scale (YMRS) ⩾ 30% or Clinical Global Impression (CGI)-Improvement ⩽ 2 ( p = 0.23), or by the more stringent definition of a reduction in YMRS ⩾ 50% ( p = 0.61). Conclusion: Pediatric BP can be effectively treated with the abovementioned medications in the context of comorbid CD. Based on previous research showing that remission of BP is associated with remission of CD, if confirmed, these findings raise the possibility that antimanic treatment of youth with BP comorbid with CD could have secondary benefits in mitigating the morbidity associated with CD. This is a pilot scale finding, the results of which are promising and should be confirmed by larger and long-term follow-up studies.
- 5 May 2022
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 36 (5) , 637-644
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole
Background: Pediatric bipolar disorder (BP) is frequently comorbid with conduct disorder (CD) and its presence adds to the morbidity of BP. While there are no known pharmacological treatments for CD, pediatric BP is responsive to treatment with medications initially indicated for the treatment of psychosis, several of which have Food and Drug Administration (FDA) approval for the treatment of pediatric mania. Aims: The main aim of this secondary analysis was to examine whether pediatric BP comorbid with CD responds similarly to treatment with such selected medications. Considering the well-documented morbidity of CD, this finding could have important clinical and public health significance. Methods: We conducted a secondary analysis of six prospective 8-week open-label trials of selected medications (risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) using identical methodology in youth with BP with and without comorbid CD. Results: Of 165 youths with BP, 54% ( N = 89) met criteria for comorbid CD. The antimanic effects observed did not significantly differ between BP youths with and without comorbid CD, as measured either by a reduction in Young Mania Rating Scale (YMRS) ⩾ 30% or Clinical Global Impression (CGI)-Improvement ⩽ 2 ( p = 0.23), or by the more stringent definition of a reduction in YMRS ⩾ 50% ( p = 0.61). Conclusion: Pediatric BP can be effectively treated with the abovementioned medications in the context of comorbid CD. Based on previous research showing that remission of BP is associated with remission of CD, if confirmed, these findings raise the possibility that antimanic treatment of youth with BP comorbid with CD could have secondary benefits in mitigating the morbidity associated with CD. This is a pilot scale finding, the results of which are promising and should be confirmed by larger and long-term follow-up studies.
- 21 December 2020
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 35 (3) , 203-210
Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature
Aim: To assess the empirical evidence for the treatment of attention deficit/hyperactivity disorder (ADHD) in populations with autism spectrum disorder (ASD). Methods: A systemic PubMed, PsychINFO, Embase, and Medline database search of peer-reviewed literature was conducted. Included in the review were controlled trials published in English with sample sizes ⩾10 participants examining the safety and efficacy of anti-ADHD medication in ASD populations. Data was extracted on relevant variables of study design, demographics, associated psychopathology, medication dose, efficacy, and tolerability. Results: Nine controlled trials met the inclusion and exclusion criteria: five with methylphenidate, three with atomoxetine, and one with guanfacine. Sample sizes ranged from 10 to 128 with 430 children participating across all the trials. In all the trials, treatment response was significantly superior to placebo. However, almost all trials assessed only hyperactivity, and most included only participants with intellectual disability with high levels of irritability. None of the trials distinguished agitation from hyperactivity. The response on hyperactivity for methylphenidate and atomoxetine was less than that observed in the neurotypical population; however, the response for guanfacine surpassed results observed in neurotypical populations. Treatment-emergent mood lability (i.e. mood dysregulation and mood-related adverse events) was frequently associated with methylphenidate and guanfacine treatments. Worse treatment outcomes were associated with individuals with lower intellectual capability compared with those with higher IQs. Conclusions: here is a scarcity of controlled trials examining ADHD treatments in ASD populations, particularly in intellectually capable individuals with ASD and in adults. Response to ADHD medications in ASD were adversely moderated by the presence of intellectual disability and mood lability.
- 21 December 2020
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 35 (3) , 203-210
Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature
Aim: To assess the empirical evidence for the treatment of attention deficit/hyperactivity disorder (ADHD) in populations with autism spectrum disorder (ASD). Methods: A systemic PubMed, PsychINFO, Embase, and Medline database search of peer-reviewed literature was conducted. Included in the review were controlled trials published in English with sample sizes ⩾10 participants examining the safety and efficacy of anti-ADHD medication in ASD populations. Data was extracted on relevant variables of study design, demographics, associated psychopathology, medication dose, efficacy, and tolerability. Results: Nine controlled trials met the inclusion and exclusion criteria: five with methylphenidate, three with atomoxetine, and one with guanfacine. Sample sizes ranged from 10 to 128 with 430 children participating across all the trials. In all the trials, treatment response was significantly superior to placebo. However, almost all trials assessed only hyperactivity, and most included only participants with intellectual disability with high levels of irritability. None of the trials distinguished agitation from hyperactivity. The response on hyperactivity for methylphenidate and atomoxetine was less than that observed in the neurotypical population; however, the response for guanfacine surpassed results observed in neurotypical populations. Treatment-emergent mood lability (i.e. mood dysregulation and mood-related adverse events) was frequently associated with methylphenidate and guanfacine treatments. Worse treatment outcomes were associated with individuals with lower intellectual capability compared with those with higher IQs. Conclusions: here is a scarcity of controlled trials examining ADHD treatments in ASD populations, particularly in intellectually capable individuals with ASD and in adults. Response to ADHD medications in ASD were adversely moderated by the presence of intellectual disability and mood lability.
- 1 October 2020
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 59 (10) , S135-S136
DIAGNOSTIC AND TREATMENT CHALLENGES: AN AUTISM SPECTRUM DISORDER UPDATE FOR CLINICIANS
- 1 October 2020
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 59 (10) , S135-S136
DIAGNOSTIC AND TREATMENT CHALLENGES: AN AUTISM SPECTRUM DISORDER UPDATE FOR CLINICIANS